# InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs

This article has been disseminated on behalf of Cybin Inc. and may include paid advertising.

 Cybin (NYSE American: CYBN) (Cboe CA: CYBN) reported second-quarter 2025 results and recent business highlights, noting strong institutional demand for its completed financing, which Interim CEO Eric So said reinforces confidence in the company’s science, differentiated therapeutic candidates and ability to execute as it advances toward key 2026 data readouts. Cybin completed enrollment in its Phase 2 CYB004 study for GAD, continued progressing CYB003 through the Phase 3 APPROACH and EXTEND trials, and secured additional global regulatory approvals to initiate the EMBRACE(R) Phase 3 study for adjunctive MDD treatment. The company expanded its intellectual property estate to more than 100 granted patents and over 250 pending applications, while its Board formed a committee to conduct a CEO search to guide the next stage of growth and late-stage clinical development.

 To view the full press release, visit https://ibn.fm/qQlOz

 About Cybin

 Cybin(R) is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

 With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

 Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.

 NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-cybin-inc-nyse-american-cybn-cboe-ca-cybn-reports-q2-2025-results-and-advances-late-stage-neuropsychiatry-programs/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cybin-advances-psychedelic-therapies-with-strong-q2-results-key-milestones/030b6706656bb20763046b62dd3fee0b) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2511/13/linengnF.webp)